Cargando…

TIPS-20 A RANDOMIZED, CONTROLLED TRIAL OF BERUBICIN, A TOPOISOMERASE II POISON THAT APPEARS TO CROSS THE BLOOD-BRAIN BARRIER (BBB), AFTER FIRST-LINE THERAPY FOR GLIOBLASTOMA MULTIFORME (GBM): PRELIMINARY RESULTS

Berubicin is a doxorubicin (Dox) analog that appears to cross the BBB with significant central nervous system (CNS) uptake. Berubicin prolongs survival in orthotopic mouse intracranial models with greater infiltration of the tumor compared to normal tissue. A Phase 1 dose-escalation study showed mye...

Descripción completa

Detalles Bibliográficos
Autores principales: Silberman, Sandra, Hsu, Sigmund, Muzyczenko, Zena, Picker, Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402321/
http://dx.doi.org/10.1093/noajnl/vdad070.150
_version_ 1785084849223106560
author Silberman, Sandra
Hsu, Sigmund
Muzyczenko, Zena
Picker, Donald
author_facet Silberman, Sandra
Hsu, Sigmund
Muzyczenko, Zena
Picker, Donald
author_sort Silberman, Sandra
collection PubMed
description Berubicin is a doxorubicin (Dox) analog that appears to cross the BBB with significant central nervous system (CNS) uptake. Berubicin prolongs survival in orthotopic mouse intracranial models with greater infiltration of the tumor compared to normal tissue. A Phase 1 dose-escalation study showed myelosuppression as the dose-limiting toxicity, with 1 complete response (14+ years), 1 partial response durable for 12 weeks, and 9 patients with stable disease for a clinical benefit rate of 44%. A trial of Berubicin vs Lomustine in patients with recurrent GBM after first-line therapy in the US and Europe is enrolling patients in a 2:1 randomization design of Berubicin:Lomustine. Patients will be stratified by MGMT methylation status. The primary endpoint is overall survival (OS). A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have reached the primary endpoint. Currently, 97 patients are enrolled with 65 in the Berubicin arm and 32 in the Lomustine arm. At present these patients show comparable demographics, with an unmethylated MGMT population of ~60% in both arms. Patients with all grades of adverse events were 80% and 69% on the Berubicin and Lomustine arms, respectively. Grade 3-4 events were 43% (Berubicin arm) and 38% (Lomustine arm), although less than or equal to 5% of patients discontinued the study due to these events. The data available shows that Berubicin and Lomustine arms are presently balanced with relatively comparable safety profiles. The study is continuing to evaluate the efficacy of this novel drug candidate and potentially provide therapeutic options for patients after first-line therapy. An updated profile of the patient population, safety, and initial efficacy will be presented.
format Online
Article
Text
id pubmed-10402321
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104023212023-08-05 TIPS-20 A RANDOMIZED, CONTROLLED TRIAL OF BERUBICIN, A TOPOISOMERASE II POISON THAT APPEARS TO CROSS THE BLOOD-BRAIN BARRIER (BBB), AFTER FIRST-LINE THERAPY FOR GLIOBLASTOMA MULTIFORME (GBM): PRELIMINARY RESULTS Silberman, Sandra Hsu, Sigmund Muzyczenko, Zena Picker, Donald Neurooncol Adv Final Category: Trials in Progress Berubicin is a doxorubicin (Dox) analog that appears to cross the BBB with significant central nervous system (CNS) uptake. Berubicin prolongs survival in orthotopic mouse intracranial models with greater infiltration of the tumor compared to normal tissue. A Phase 1 dose-escalation study showed myelosuppression as the dose-limiting toxicity, with 1 complete response (14+ years), 1 partial response durable for 12 weeks, and 9 patients with stable disease for a clinical benefit rate of 44%. A trial of Berubicin vs Lomustine in patients with recurrent GBM after first-line therapy in the US and Europe is enrolling patients in a 2:1 randomization design of Berubicin:Lomustine. Patients will be stratified by MGMT methylation status. The primary endpoint is overall survival (OS). A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have reached the primary endpoint. Currently, 97 patients are enrolled with 65 in the Berubicin arm and 32 in the Lomustine arm. At present these patients show comparable demographics, with an unmethylated MGMT population of ~60% in both arms. Patients with all grades of adverse events were 80% and 69% on the Berubicin and Lomustine arms, respectively. Grade 3-4 events were 43% (Berubicin arm) and 38% (Lomustine arm), although less than or equal to 5% of patients discontinued the study due to these events. The data available shows that Berubicin and Lomustine arms are presently balanced with relatively comparable safety profiles. The study is continuing to evaluate the efficacy of this novel drug candidate and potentially provide therapeutic options for patients after first-line therapy. An updated profile of the patient population, safety, and initial efficacy will be presented. Oxford University Press 2023-08-04 /pmc/articles/PMC10402321/ http://dx.doi.org/10.1093/noajnl/vdad070.150 Text en © The Author(s) 2023. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Final Category: Trials in Progress
Silberman, Sandra
Hsu, Sigmund
Muzyczenko, Zena
Picker, Donald
TIPS-20 A RANDOMIZED, CONTROLLED TRIAL OF BERUBICIN, A TOPOISOMERASE II POISON THAT APPEARS TO CROSS THE BLOOD-BRAIN BARRIER (BBB), AFTER FIRST-LINE THERAPY FOR GLIOBLASTOMA MULTIFORME (GBM): PRELIMINARY RESULTS
title TIPS-20 A RANDOMIZED, CONTROLLED TRIAL OF BERUBICIN, A TOPOISOMERASE II POISON THAT APPEARS TO CROSS THE BLOOD-BRAIN BARRIER (BBB), AFTER FIRST-LINE THERAPY FOR GLIOBLASTOMA MULTIFORME (GBM): PRELIMINARY RESULTS
title_full TIPS-20 A RANDOMIZED, CONTROLLED TRIAL OF BERUBICIN, A TOPOISOMERASE II POISON THAT APPEARS TO CROSS THE BLOOD-BRAIN BARRIER (BBB), AFTER FIRST-LINE THERAPY FOR GLIOBLASTOMA MULTIFORME (GBM): PRELIMINARY RESULTS
title_fullStr TIPS-20 A RANDOMIZED, CONTROLLED TRIAL OF BERUBICIN, A TOPOISOMERASE II POISON THAT APPEARS TO CROSS THE BLOOD-BRAIN BARRIER (BBB), AFTER FIRST-LINE THERAPY FOR GLIOBLASTOMA MULTIFORME (GBM): PRELIMINARY RESULTS
title_full_unstemmed TIPS-20 A RANDOMIZED, CONTROLLED TRIAL OF BERUBICIN, A TOPOISOMERASE II POISON THAT APPEARS TO CROSS THE BLOOD-BRAIN BARRIER (BBB), AFTER FIRST-LINE THERAPY FOR GLIOBLASTOMA MULTIFORME (GBM): PRELIMINARY RESULTS
title_short TIPS-20 A RANDOMIZED, CONTROLLED TRIAL OF BERUBICIN, A TOPOISOMERASE II POISON THAT APPEARS TO CROSS THE BLOOD-BRAIN BARRIER (BBB), AFTER FIRST-LINE THERAPY FOR GLIOBLASTOMA MULTIFORME (GBM): PRELIMINARY RESULTS
title_sort tips-20 a randomized, controlled trial of berubicin, a topoisomerase ii poison that appears to cross the blood-brain barrier (bbb), after first-line therapy for glioblastoma multiforme (gbm): preliminary results
topic Final Category: Trials in Progress
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402321/
http://dx.doi.org/10.1093/noajnl/vdad070.150
work_keys_str_mv AT silbermansandra tips20arandomizedcontrolledtrialofberubicinatopoisomeraseiipoisonthatappearstocrossthebloodbrainbarrierbbbafterfirstlinetherapyforglioblastomamultiformegbmpreliminaryresults
AT hsusigmund tips20arandomizedcontrolledtrialofberubicinatopoisomeraseiipoisonthatappearstocrossthebloodbrainbarrierbbbafterfirstlinetherapyforglioblastomamultiformegbmpreliminaryresults
AT muzyczenkozena tips20arandomizedcontrolledtrialofberubicinatopoisomeraseiipoisonthatappearstocrossthebloodbrainbarrierbbbafterfirstlinetherapyforglioblastomamultiformegbmpreliminaryresults
AT pickerdonald tips20arandomizedcontrolledtrialofberubicinatopoisomeraseiipoisonthatappearstocrossthebloodbrainbarrierbbbafterfirstlinetherapyforglioblastomamultiformegbmpreliminaryresults